Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-12 am EST			5-day change	1st Jan Change
0.0280 ^EUR	-5.41%		-2.78%	-10.83%

25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE

Highlights

25-09-29	GeNeuro Secures Debt-restructuring Moratorium Extension from Swiss Court	MT
25-09-26	Geneuro SA announces extension of its definitive Debt Restructuring moratorium	RE
25-07-16	Court Orders GeNeuro Subsidiary's Liquidation	MT
25-06-12	Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas	RE
25-05-28	GeNeuro Receives Debt-restructuring Moratorium from Swiss Court	MT
24-09-20	Geneuro: presentation of new Temelimab data
24-07-15	GeNeuro to Apply for Debt Moratorium in Switzerland	MT
24-06-28	GeNeuro: failure of phase 2 study in Covid long
24-06-28	GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome	CI
24-05-16	GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	CI
24-02-04	GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-02	GeNeuro: share price falls after private placement
24-01-05	GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold
23-12-11	Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	CI
23-11-28	GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	CI
23-10-19	GeNeuro and Verily Collaborate to Advance Long-COVID Research	CI
23-09-29	GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-09-27	GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS	CI
23-09-11	GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients	CI
23-04-05	GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-07	GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial	MT
22-11-16	GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab	CI
22-10-28	Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms	CI
22-10-25	GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis	CI
22-09-29	GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Highlights

Filters